Welcome to
OzStar Therapeutics

In Pursuit of the best Treatment for Type 2 Diabetes.

Aglucator™ is a first-in-class patented Medical Prebiotic developed to improve effectiveness of sulphonylurea class of anti-diabetes drugs such as glybenclamide, gliclazide, glipizide and glimepiride. Combintation use of Aglucator™ and sulphonylurea class drugs can halt diabetes progression and the need for expensive anti-diabetes drugs and insulin injections!
Our Company

A goal-oriented and accomplished company

OzStar Therapeutics Pty Ltd was founded in April 2010 to develop a novel first-in-class treatment for type 2 diabetes. The company received two Commercialisation Australia Government grants to conduct commercial and regulatory due diligence on its technology and to conduct a phase 2 clinical trial, both of which have been completed successfully.

Our mission is to provide a natural treatment replacing the need for multiple drug therapies and insulin injections for type 2 diabetes patients.

Our vision is to make Aglucator™ the number one Medical Prebiotic for the treatment of type 2 diabetes.

Dr. Nick N Gorgani, BE, MBBS, MS Drug Dev, Phd

Founder, President and CEO of OzStar Therapeutics Pty Ltd

Our Values

We Believe in Perseverance and Unmatched Science


Through conduct of world-class research for over a decade our team have discovered a novel approach that may assist in ending the diabetes pandemic!

Over a decade of relentless R&D efforts have specifically developed Aglucator™ to rejuvinate sulphonylurea class anti-diabetes drugs.


Built from a seasoned, highly experienced and dedicated directors, executive team, and scientific/medical advisory board memebrs, OzStar Therapeutics moving towards becoming one of the world’s best pharmaceutical companies.


One treatment forever! 

OzStar Therapeutics is proud to own a novel technology that can serve type 2 diabetes patients for decades to come.   In contrast to currently available treatments that lose effectiveness, our adjunctive Aglucator™ treatment specifically targets patient’s gut microbiome to provide significant and sustained blood glucose and HbA1c control.


Directors, executive team and advisory members of OzStar Therapeutics are eminent individuals whom contributed enourmously to the field of their expertise with integrity and respect. 


Based on long term clinical case studies, our treatment, not only delays the need for expensive drug use and insulin injections, it forecasts to reduce the need for continuous blood glucose and HbA1c monitoring.


OzStar will relentlessly continue until our novel treatment is being tested and adapted by hundreds of millions of type 2 diabetes patients, worldwide.

Our Products

Committed to Quality, Safety and Sustained Effectiveness

Clinical Development

OzStar Therapeutics conducted several long term clinical case studies and an Australian Government backed clinical trial that shows promising treatment regimen for type 2 diabetes.

Regulatory & Access

Through rigouros due diligence, OzStar Therapeutics fullfilled all requirements to launch its first-in-class product Aglucator™ in Australia as food for special medical purpose.

Intellectual Properties and Trademarks

Within the past decade, OzStar Therapeutics receivd two families of patents granted in 14 major countries possessing highest number of diabetes patients. OzStar Therapeutics obtained trademark for Aglucator™.

Scientific Exchange

At OzStar Therapeutics we are committed to contribute to the scientific community we engged with. Our clinical trial results presented at the European Association for the Study of Diabetes. Subsequenslty, our trial results were peer-reviewed and published in an international journal.

OzStar CEO has been invited as a keynote speaker in a number related international conferences.

Our Purpose

To serve type 2 diabetes patients who deserve better treatments.

Type 2 diabetes is considered a progressive disease becasue of its chronic nature and loss of effectiveness of currently available treatments.   

  • You may ask:
  • What is the main driving force (ethiology) behind the development and progression of type 2 diabetes?
  • Why currently marketed drugs lose effectiveness?

We have plenty of emerging scientific information to share with you. Click Health Care Professionals

Our Brands